

NAME
FULL CONTACT INFORMATION
PHONE
EMAIL
DATE

Education

- 2005-2006 **M.P.H.**, Harvard School of Public Health
 Boston, MA
 Concentration: Quantitative Methods
Practicum Project: Measures of Energy Balance and Mammographic Density in the Nurses' Health Study.
 Advisors: Graham A. Colditz, MD, DrPH and Rulla M. Tamimi, ScD
 Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School
- 1997-2004 **Ph.D.**, University of California, San Diego
 La Jolla, California
 Biomedical Sciences Graduate Program
Dissertation Title: The Cellular Pharmacology and Cytotoxic Activity of Cisplatin are Modulated by the Copper Transporter ATP7A.
 Laboratory of Stephen B. Howell, MD
- 1993-1997 **B.S.**, University of California, Los Angeles
 Los Angeles, California
 Major: Microbiology and Molecular Genetics

Professional Experience

- 2005-present **Cancer Prevention Fellow**
 Cell and Cancer Biology Branch, Center for Cancer Research
 National Cancer Institute, NIH, Bethesda, MD
Post-Doctoral Project: Expression Profiling of Microdissected Stroma from Normal and Malignant Ovary.
 Laboratory of Michael J. Birrer, MD, PhD
- 2004-2005 **Post-Doctoral Fellow**
 Rebecca and John Moores UCSD Cancer Center
 University of California, San Diego, La Jolla, California
Project Title: Characterization of the Cellular Pharmacology of JM-118.
 Laboratory of Stephen B. Howell, MD

Honors and Awards

- 2008 Fellows Award for Research Excellence (FARE)
 National Institutes of Health, Bethesda, MD
- 2008 Merit Award (for productivity and service to the program)
 Cancer Prevention Fellowship Program, NCI, Bethesda, MD
- 2008 Best Basic Science Poster Presentation
 Society of Gynecological Oncologists 39th Annual Meeting on Women's Cancer
 Chicago, IL.

2007	Fellows Award for Research Excellence (FARE) National Institutes of Health, Bethesda, MD
2003	AACR-AFLAC Scholar-in-Training Award American Association for Cancer Research, Philadelphia, PA
2002	AACR Travel Award Rebecca and John Moores UCSD Cancer Center, La Jolla, CA
2001	AACR-BD Pharmingen Scholar-in-Training Award American Association for Cancer Research, Philadelphia, PA
1997	Graduated <i>Cum Laude</i> , University of California, Los Angeles, Los Angeles, California

Funding

2005-present	Cancer Prevention Fellowship, National Cancer Institute
2008	NIH/NCI K99/R00 Pathway To Independence Award "Characterization of Stromal-Epithelial Interactions in Ovarian Cancer" <i>Under Review</i>

Teaching and Mentoring Experience

2008	Invited Lecturer, "Translational Research in Ovarian Cancer" Advanced Topics in Cancer Epidemiology Course Harvard School of Public Health, Boston, MA
2008	Invited Lecturer, "Oncogenes and Tumor Suppressor Genes" Molecular Prevention Course NCI Summer Curriculum in Cancer Prevention, Rockville, MD
2006-2008	Laboratory mentor, post-baccalaureate fellow.
2000-2004	Laboratory mentor, 2 graduate students, 2 undergraduate students and a lab technician.
1999	Teaching Assistant Genetics Course (BICD100, Dr. Stuart Brody), Division of Biological Sciences University of California, San Diego, La Jolla, CA
1999	Invited Lecturer, "Genetics and Cancer" Genetics Course (BICD100, Dr. Stuart Brody), Division of Biological Sciences University of California, San Diego, La Jolla, CA
1996-1997	Teaching Assistant Supervisor, Biology and Chemistry College Tutorial Services, University of California, Los Angeles
1995-1997	Undergraduate Teaching Assistant, Organic Chemistry College Tutorial Services, University of California, Los Angeles

Professional Service and Leadership

2008	Chief Judge, NIH Fellows Award for Research Excellence Study Section: Angiogenesis
------	---

2008, 2009	NIH/Office of Training and Education 1 st and 2 nd Annual Career Symposium Planning Committee
2008-present	Founding Co-Chair, Fellows Advisory Board, Cancer Prevention Fellowship Program, National Cancer Institute
2007-present	NIH Fellows Committee (FelCom), Cancer Prevention Fellowship Program Representative, Co-Chair, Career Development Subcommittee
2007	Co-chair, 6 th Annual Cancer Prevention Fellows' Research Symposium, National Cancer Institute, Bethesda, MD
2007	Poster Judge, NIH Annual Graduate Student Research Symposium
2007	Chief Judge, NIH Fellows Award for Research Excellence Study Section: Pharmacology and Toxicology/Environmental Health,
2002	Graduate Program External Review Committee, Graduate Student Representative, University of California, San Diego
2001-2003	Biomedical Sciences Graduate Program Core Committee, Graduate Student Representative, University of California, San Diego
2000	Admissions Committee, Biomedical Sciences Graduate Program, University of California, San Diego

Society Memberships

Associate Member, American Association for Cancer Research
Member, Women in Cancer Research, American Association for Cancer Research
Member, Tumor Microenvironment Working Group, American Association for Cancer Research
Member, Translational Research Interest Group, National Institutes of Health

Abstracts

Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS and Howell SB. MLH1 and MSH2 expression and correlation with prognostic factors in ovarian cancer. Proc. Am. Assoc. Cancer Res., #4623, 2000. **Selected for poster discussion section.**

Samimi G, Mishima M, Breaux J, Stuart RO, Berry C, Los G and Howell SB. Biochemical and gene expression analysis of oxaliplatin-resistant cell lines. American Association for Cancer Research Oncogenomics Conference, 2001.

Samimi G, Mishima M, Breaux JK, Stuart RO, Berry CC, Los G and Howell SB. Investigation of the gene expression profiles of oxaliplatin-resistant cell lines using microarray data. Proc. Am. Assoc. Cancer Res., #2277, 2001. **Selected for poster discussion section. Selected for AACR-BD Pharmingen Scholar in Training Award.**

Samimi G, Safaei R, Katano K, Naerdemann W, Holzer AK and Howell SB. Expression of the copper transporter ATP7A modulates cisplatin transport. Proc. Am. Assoc. Cancer Res., #2102, 2002. **Selected for UCSD Moores Cancer Center Travel Award.**

- Samimi G, Manorek G, Castel R, Breaux JK, Berry CC, Los G and Howell SB. Identification of genes differentially expressed in isogenic oxaliplatin-sensitive and resistance human tumor cells. American Association for Cancer Research Oncogenomics Conference, 2003.
- Samimi G, Katano K, Holzer AK, Safaei R, Petris MJ and Howell SB. The copper export transporters ATP7A and ATP7B modulate the cellular pharmacology of cisplatin and carboplatin. Proc. Am. Assoc. Cancer Res., #4036, 2003. **Selected for poster discussion section.**
- Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS and Howell, SB. Expression of the copper transporter ATP7A is associated with poor survival of ovarian cancer patients treated with platinum drugs. Proc. Am. Assoc. Cancer Res., #4037, 2003. **Selected for poster discussion section. Selected for AACR-AFLAC Scholar in Training Award.**
- Samimi G and Howell SB. The effect of copper transporters ATP7A and ATP7B on the cytotoxicity and cellular pharmacology of JM-118. Proc. Am. Assoc. Cancer Res., #4110, 2005.
- Samimi G, Bonome T, Radonovich M, Pise-Maison C, Brady J, Ghosh S, Ng S-W, Mok SC and Birrer MJ. Expression profiling of stroma from ovarian cancers reveals altered signaling pathways. Society of Gynecological Oncologists 38th Annual Meeting on Women's Cancer, #B-281, 2007.
- Samimi G, Bonome T, Radonovich M, Pise-Maison C, Brady J, Ghosh S, Ng S-W, Mok SC and Birrer MJ. Gene expression profiling of microdissected stroma from normal ovary and ovarian tumors reveals altered expression of genes implicated in adhesion and angiogenesis. Proc. Am. Assoc. Cancer Res., #2960, 2007.
- Samimi G, Bonome T, Radonovich M, Pise-Maison C, Brady J, Ghosh S, Ng S-W, Mok SC and Birrer MJ. Gene expression profiling of microdissected stroma from normal and malignant ovary identifies a role for CTGF in ovarian tumor progression. American Association for Cancer Research Centennial Conference on Translational Cancer Medicine, #A75, 2007.
- Samimi G, Bonome T, Radonovich M, Pise-Maison C, Brady J, Ghosh S, Ng S-W, Mok SC and Birrer MJ. Multiple ligands of integrin $\alpha\beta 3$ are up-regulated in ovarian tumor stroma: important tumor-stroma interaction. Society of Gynecological Oncologists 39th Annual Meeting on Women's Cancer, #110, 2008. **Selected Best Basic Science Poster Presentation.**
- Samimi G, Bonome T, Ghosh S, Ng S-W, Mok SC and Birrer MJ. Tumor-stroma interactions in ovarian cancer: The role of CTGF in ovarian tumor biology. Proc. Am. Assoc. Cancer Res., #5379, 2008.

Publications

- Samimi G**, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS and Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. *Clin Cancer Res* 6(4):1415-1421, 2000.
- Los G, Yang F, **Samimi G**, Manorek G, Guerorgueva IM, Howell SB, van Erp N and Breaux JK. Using mRNA expression profiling to determine anticancer drug efficacy. *Cytometry* 47(1):66-71, 2002.
- Seely LB, **Samimi G** and Webster NJG. Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. *BMC Cancer* 2:15, 2002.

- Mishima M, **Samimi G (co-first authors)**, Kondo A, Lin X and Howell SB. The cellular pharmacology of oxaliplatin resistance. *Eur J of Cancer* 38(10):1405-1412, 2002.
- Katano K, Kondo A, Safaei R, Holzer A, **Samimi G**, Mishima M, Kuo Y, Rochdi M and Howell SB. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. *Cancer Res* 62(22):6559-6565, 2002.
- Katano K, Safaei R, **Samimi G**, Holzer A, Rochdi M and Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin on ovarian carcinoma cells. *Mol Pharmacol* 64(2):466-473, 2003.
- Safaei R, Katano K, **Samimi G**, Naerdemann W, Stevenson JL and Howell SB. Cross-resistance between copper and cisplatin: Analysis of cellular pharmacokinetic mechanisms. *Cancer Chemother Pharmacol* 53(3):239-246, 2004.
- Samimi G**, Varki NM, Wilczynski S, Safaei R, Alberts DS and Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. *Clin Cancer Res* 9(16 pt 1):5853-5859, 2003. **Cover Article (side-bar)**.
- Accompanying Editorial:** Kruh GD. Lustrous insights into cisplatin accumulation: copper transporters. *Clin Cancer Res* 9(16 pt 1):5807-5809, 2003.
- Samimi G**, Katano K, Holzer AK, Safaei R and Howell SB. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. *Mol Pharmacol* 66(1):25-32, 2004.
- Holzer AK, **Samimi G**, Katano K, Naerdemann W, Lin X, Safaei R and Howell SB. The copper influx transporter hCTR1 regulates the uptake of cisplatin in human ovarian carcinoma cells. *Mol Pharmacol* 66(4):25-32, 2004.
- Katano K, Safaei R, **Samimi G**, Holzer AK, Tomioka M, Goodman M and Howell SB. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. *Clin Cancer Res* 10(13):4578-4588, 2004.
- Samimi G**, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Safaei R and Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin and oxaliplatin in ovarian cancer cells. *Clin Cancer Res* 10(14):4661-4669, 2004. **Cover Article (figure)**.
- Safaei R, Holzer AK, Katano K, **Samimi G** and Howell SB. The role of copper transporters in the development of resistance to Pt drugs. *J Inorg Biochem* 98(10):1607-13, 2004.
- Samimi G**, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G and Howell SB. cDNA microarray-based identification of genes and mechanisms associated with oxaliplatin resistance. *Cancer Chemother and Pharmacol* 55(1):1-11, 2005.
- Safaei R, Katano K, Larson BJ, **Samimi G**, Holzer AK, Naerdemann W, Tomioka M, Goodman M and Howell SB. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. *Clin Cancer Res* 11(2 Pt 1):756-767, 2005.

Samimi G and Howell SB. Modulation of the cellular pharmacology of JM-118, the major metabolite of satraplatin, by copper influx and efflux transporters. *Cancer Chemother Pharmacol* 57(6):781-788, 2006.

Cheng TC, Manorek G, **Samimi G**, Lin X, Berry CC and Howell SB. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. *Cancer Chemother Pharmacol* 58(3):384-395, 2006.

Samimi G, Kishimoto S, Manorek G, Breaux JK and Howell SB. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM-118 the major metabolite of satraplatin. *Cancer Chemother Pharmacol* 59(3):301-312, 2007.

Samimi G, Colditz GA, Baer HJ and Tamimi RM. Measures of energy balance and mammographic density in the Nurses' Health Study. *Breast Cancer Res Treat* Jun 26, 2007.

Mok SC, Kwon J, Welch WR, **Samimi G**, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS and Wong K-K. Etiology and pathogenesis of epithelial ovarian cancer. *Disease Markers* 23(5-6):367-376, 2007.

Samimi G, Ozbun L, Johnson ME, Mok SC and Birrer MJ. Biomarkers of mucinous tumors of the ovary. *Disease Markers* 23(5-6):389-396, 2007.

Farley J, Ozbun L, **Samimi G** and Birrer MJ. Cell cycle and related protein. *Disease Markers* 23(5-6):433-443, 2007.

Samimi G, Bonome T, Radonovich M, Pise-Maison C, Brady J, Ghosh S, Ng S-W, Mok SC and Birrer MJ. Gene expression profiling of microdissected stroma from normal and malignant ovary identifies a role for CTGF in ovarian tumor progression. *Under review, Cancer Research*.

Mok SC, Bonome T, Bell A, Johnson ME, Park D-C, Hao K, Yip DKP, Donninger H, Ozbun L, **Samimi G**, Brady J, Radonovich M, Barrett JC, Wong WH, Welch WR, Berkowitz RS and Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: microfibril-associated glycoprotein 2. *Under re-review, Cancer Cell*.